Resistance of O-acetylated gonococcal peptidoglycan to human peptidoglycan-degrading enzymes
- 1 June 1983
- journal article
- research article
- Published by American Society for Microbiology in Infection and Immunity
- Vol. 40 (3) , 903-911
- https://doi.org/10.1128/iai.40.3.903-911.1983
Abstract
Two naturally occurring forms of gonococcal peptidoglycan (PG) were tested for their susceptibility to human PG hydrolases. Purified 3H-labeled PG substituted extensively with O-acetyl derivatives (O-PG; from Neisseria gonorrhoeae FA19) and 14C-labeled O-acetyl-deficient PG (non-O-PG; from N. gonorrhoeae RD5) were mixed together and treated with either normal human sera (NHS) or with lysozyme purified from human polymorphonuclear leukocytes (PMN-LZ). The initial rate of hydrolysis of O-PG by NHS or by PMN-LZ was two- to fourfold less than that of its non-O-PG counterpart in the same tube. When the reactions were allowed to go to completion. NHS solubilized both PGs completely, whereas PMN-LZ solubilized all of the non-O-PG and left ca. 60% of the O-PG insoluble. The PMN-LZ-soluble fraction of O-PG consisted largely of glycosidically linked fragments with molecular weights greater than ca. 10(4), whereas the corresponding non-O-PG was degraded to lower-molecular-weight fragments, exclusively. At completion, NHS hydrolyzed both PGs to fragments whose size was equal to or smaller than that of the free disaccharide unit of PG, suggesting that human sera contain a peptide-splitting (amidase) activity and a glycosidase activity, in addition to that of the well-known muramidase. NHS also promoted the release of high-molecular-weight PG fragments from intact gonococci. The persistence of human hydrolase-resistant PG in the form of soluble macromolecular fragments may potentiate the biological effects of gonococcal PG in vivo.This publication has 34 references indexed in Scilit:
- Measurement of bacterial cell wall in tissues by solid-phase radioimmunoassay: correlation of distribution and persistence with experimental arthritis in ratsInfection and Immunity, 1982
- RELATIONSHIP OF COMPLEMENT TO EXPERIMENTAL ARTHRITIS INDUCED IN RATS WITH STREPTOCOCCAL CELL-WALLS1982
- The metabolic fate of 14C-labeled immunoadjuvant peptidoglycan monomerII. In vitro studiesBiochimica et Biophysica Acta (BBA) - General Subjects, 1981
- Effect of penicillin G on release of peptidoglycan fragments by Neisseria gonorrhoeae: characterization of extracellular productsAntimicrobial Agents and Chemotherapy, 1981
- THE RELATION OF EXPERIMENTAL ARTHRITIS TO THE DISTRIBUTION OF STREPTOCOCCAL CELL-WALL FRAGMENTS1980
- Biological activities of muramyl dipeptide, a synthetic glycopeptide analogous to bacterial immunoregulating agents.1978
- Structural Requirements for Arthritogenicity of Peptidoglycans from Staphylococcus Aureus and Lactobacillus Plantarum and Analogous Synthetic CompoundsThe Journal of Immunology, 1976
- Antipeptidoglycan in Rheumatic Fever: Agreement with CarditisExperimental Biology and Medicine, 1973
- The Wall Peptidoglycans of Neisseria perflava, Moraxella glucidolytica, Pseudomonas alcaligenes and Proteus vulgaris Strain P18European Journal of Biochemistry, 1973
- Streptococcal Anti-Group A Precipitins in Sera from Patients with Rheumatic Arthritis and Acute GlomerulonephritisInternational Archives of Allergy and Immunology, 1970